Point72 Asia Singapore Pte. Ltd. Takes Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Point72 Asia Singapore Pte. Ltd. purchased a new position in Protalix BioTherapeutics, Inc. (NYSE:PLX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 68,163 shares of the company’s stock, valued at approximately $80,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.09% of Protalix BioTherapeutics at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Protalix BioTherapeutics during the first quarter valued at $198,000. Ground Swell Capital LLC bought a new stake in shares of Protalix BioTherapeutics in the 2nd quarter valued at approximately $73,000. Cubist Systematic Strategies LLC bought a new stake in shares of Protalix BioTherapeutics in the 2nd quarter valued at approximately $37,000. Finally, Squarepoint Ops LLC increased its holdings in Protalix BioTherapeutics by 673.3% in the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after buying an additional 119,949 shares during the last quarter. 16.53% of the stock is currently owned by institutional investors and hedge funds.

Protalix BioTherapeutics Price Performance

NYSE PLX opened at $1.05 on Monday. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.82 and a fifty-two week high of $1.90. The stock’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.13. The firm has a market cap of $76.98 million, a P/E ratio of 26.25 and a beta of 0.70.

Protalix BioTherapeutics (NYSE:PLX) last posted its earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.05). Protalix BioTherapeutics had a negative return on equity of 45.15% and a negative net margin of 38.62%. The company had revenue of $13.47 million during the quarter, compared to analyst estimates of $12.50 million. During the same quarter last year, the firm posted ($0.07) earnings per share. On average, equities analysts expect that Protalix BioTherapeutics, Inc. will post 0.06 EPS for the current year.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.